Savara (NASDAQ:SVRA) Stock Price Down 3.3% - Should You Sell?

Key Points

• Savara Inc. shares fell 3.3% to $3.71, with trading volume significantly lower, down 92% from its average.
• Multiple research analysts have a positive outlook, with price targets ranging from $2.00 to $11.00 and a consensus rating of "Moderate Buy".
• Director Richard J. Hawkins increased his stake by purchasing 48,225 shares at $2.04 each, signaling insider confidence in the company's potential.

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) were down 3.3% during mid-day trading on Thursday . The company traded as low as $3.73 and last traded at $3.71. Approximately 106,460 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 1,287,539 shares. The stock had previously closed at $3.83.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Guggenheim upped their price objective on shares of Savara from $8.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday. HC Wainwright increased their price objective on shares of Savara from $5.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, September 3rd. Oppenheimer lifted their price target on shares of Savara from $6.00 to $8.00 and gave the stock an "outperform" rating in a research note on Monday. Wells Fargo & Company dropped their price target on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 28th. Finally, Evercore ISI decreased their price objective on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research report on Wednesday, May 28th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Savara currently has a consensus rating of "Moderate Buy" and an average target price of $7.50.

Savara Stock Performance

The company has a debt-to-equity ratio of 0.25, a quick ratio of 11.08 and a current ratio of 11.08. The stock has a market cap of $643.66 million, a P/E ratio of -7.41 and a beta of 0.56. The firm's 50 day moving average is $2.82 and its 200 day moving average is $2.73.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Analysts anticipate that Savara Inc. will post -0.45 EPS for the current year.

Insider Transactions at Savara

In other news, Director Richard J. Hawkins purchased 48,225 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were purchased at an average cost of $2.04 per share, with a total value of $98,379.00. Following the completion of the acquisition, the director owned 115,466 shares of the company's stock, valued at approximately $235,550.64. This represents a 71.72% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.33% of the company's stock.

Hedge Funds Weigh In On Savara

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. purchased a new position in Savara during the fourth quarter valued at $37,000. Prudential Financial Inc. purchased a new position in Savara during the second quarter valued at $30,000. BNP Paribas Financial Markets lifted its holdings in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock valued at $31,000 after purchasing an additional 4,626 shares in the last quarter. May Hill Capital LLC purchased a new position in shares of Savara in the second quarter worth about $32,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Savara in the second quarter worth about $33,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.